Toll-Like Receptor Agonists in Cancer Therapy

  • Lu Y
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Toll-like receptors (TLRs) are pattern-recognition receptors related to the Drosophila Toll protein. TLR activation alerts the immune system to microbial products and initiates innate and adaptive immune responses. The naturally powerful immunostimulatory property of TLR agonists can be exploited for active immunotherapy against cancer. Antitumor activity has been demonstrated in several cancers, and TLR agonists are now undergoing extensive clinical investigation. This review discusses recent advances in the field and highlights potential opportunities for the clinical development of TLR agonists as single agent immunomodulators, vaccine adjuvants and in combination with conventional cancer therapies. © 2009 Future Medicine Ltd.

Cite

CITATION STYLE

APA

Lu, Y. (2020). Toll-Like Receptor Agonists in Cancer Therapy. Novel Approaches in Cancer Study, 4(5). https://doi.org/10.31031/nacs.2020.04.000597

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free